Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Patient satisfaction is widely recognised as a key indicator of healthcare quality, influencing patient behaviour and health outcomes. This study aimed to evaluate (1) patient satisfaction with the implementation of a pharmacist-led chronic kidney disease screening and quality use of medicines (CKD-QUM) trial in Australian community pharmacies and (2) assess the reliability and validity of the purpose-built satisfaction scale used in the survey.
The survey was administered to 1,064 trial participants from March 2024 to July 2025. In the trial, the intervention group received a CKD risk assessment using QKidney®, point-of-care (POC) serum creatinine measurement, and a review of medications, while the control group received the risk assessment only. Patient satisfaction was assessed using a 12-item, five-point Likert scale questionnaire (1 = strongly disagree to 5 = strongly agree) developed by the research team, along with additional related questions. Data were cleaned in Microsoft Excel and analysed using SPSS (version 31 for Windows). Variables with <5% missing data were imputed using the mode, while one item was excluded due to high missingness (87%). The reliability of the satisfaction scale was assessed using Cronbach’s α, and its validity was evaluated using exploratory factor analysis (EFA).
The response rate was 41.7% (444/1,064), of which data from 414 patients were included in the final analysis. More than half of the respondents were female (55.1%) and in the intervention group (54.3%), with a mean (±SD) age of 62.3±9.2 years. The 11-item satisfaction scale demonstrated good internal consistency (Cronbach’s α = 0.89) and all items contributed to the overall Cronbach’s α. Regarding perceptions of the service, the majority found it useful (76.1%), reasonable in terms of effort (98.1%) and time (97.5%), and acceptable with respect to privacy (98.5%). Patients generally agreed that pharmacists were attentive (99.5%), the counselling and education were helpful (83.3%), and test results were adequately discussed (81.7%). Nearly all respondents considered the community pharmacy setting suitable for conducting CKD risk assessment along with POC testing for screening and medication review (96.6%) and were willing to repeat the screening (96.6%) or recommend it to others (95.1%). Less than half of respondents (45.6%) were willing to pay for the service, with amounts ranging from 5 to 50 AUD (mean ±SD: 16.7±6.3 AUD). The EFA identified two factors—1. Service Process and Acceptability (comprising 7 items) and 2. Pharmacist Interaction and Education (comprising 3 items)—which together explained 55.3% of the total variance. Factor 1 accounted for 45.1% and Factor 2 for 10.2% of the variance.
This survey demonstrated high patient satisfaction with the pharmacist-led CKD screening service in Australian community pharmacies, supporting its potential for wider implementation. The satisfaction scale also showed strong reliability and construct validity, indicating that it effectively measured patient satisfaction.
